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Ultrasound-guided foam sclerotherapy is a safe
and clinically effective treatment for superficial
venous reflux
Andrew W. Bradbury, BSc, MB, ChB, MBA, MD, FRCSEd, Gareth Bate, RGN, Karl Pang, MB, ChB,
Katy A. Darvall, MB, ChB, MRCS, and Donald J. Adam, MB, ChB, MD, FRCSEd, Birmingham,
United Kingdom
Objective: To test the hypothesis that ultrasound-guided foam sclerotherapy (UGFS) is a safe and durable treatment for
superficial venous reflux (SVR) associated with CEAP clinical grade 2-6 disease.
Methods: This was an interrogation of a prospectively gathered computerized database.
Results: Between March 23, 2004 and December 31, 2009, 977 patients (1252 legs) underwent UGFS for unilateral (702
legs) or bilateral (550 legs) SVR in associationwithCEAP clinical grade 2-3 (n 868), 4 (n 232), or 5/6 (n 152) disease.
The following reflux in 1417 venous segments was treated: primary great saphenous vein (GSV) (n  745); recurrent GSV
(n 286), primary small saphenous vein (SSV) (n 189), recurrent SSV (n 50); primary anterior accessory saphenous vein
(AASV) (n  93); recurrent AASV (n  46); vein of the popliteal fossa (VOPF) (n  5), and Giacomini vein (GV) (n  3).
Three hundred forty-eight legs (27.8%) had undergone previous surgery. Three patients suffered post-UGFS deep vein
thrombosis (DVT) and one a pulmonary embolus (PE), all within the first month (0.4% venous thrombo-embolic complica-
tion rate). Five patients (0.5%) had transient visual disturbance at the time of, or shortly after, treatment. No other neurologic
or serious complications were reported. During a mean (range) follow-up of 28 (<1 to 68) months, 161 (12.9%) legs
underwent a further session ofUGFS for truncal VV at amean (range) of 17 (<1 to 63)months following the first treatment.
In 52 legs, retreatment was due to the development of new SVR and in 109 legs was for true recurrence (8.7% complete or
partial recanalization rate leading to treatment). There was no significant difference in retreatment rates between UGFS for
GSV and SSV reflux or between UGFS for primary or recurrent disease.
Conclusion: UGFS for CEAP 2-6 SVR is associated with a low complication and retreatment rate. However, as patients
are at risk of developing recurrent and new SVR they should be kept under review. Further UGFS for new or recurrent
disease is simple, safe, and effective. ( J Vasc Surg 2010;52:939-45.)Ultrasound-guided foam sclerotherapy (UGFS) is
widely used in the UK and many other countries to
eradicate superficial venous reflux (SVR).1-9 UGFS leads
to significant improvements in symptoms, venous hemo-
dynamics,10 and disease-specific and generic health-
related quality of life11,12 and is also associated with high
levels of patient satisfaction13 and significantly less mor-
bidity and a quicker return to normal activities than
surgery.14 In the short term, the results of UGFS, radio-
frequency (RFA), and endovenous LASER ablation
(EVLA) appear quite similar15,16 although UGFS is
probably more cost-effective.17 There have been some
concerns about bubbles within the foam reaching the
systemic circulation via a patent foramen ovale (PFO),
and there have been a small number of case reports of
transient neurologic events following UGFS. The etiol-
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and further studies are required.18-21 However, the fact
that visual disturbances have been reported following
liquid sclerotherapy suggests that mechanisms unrelated
to bubbles, such as vasospasm from the sclerosant itself
or secondary to vasoactive moieties released from venous
endothelium as it is destroyed, may be involved.
In the United Kingdom, after much debate and scrutiny
of the available data, the majority of vascular surgeons and
other groups treating venous disease have come to regard
UGFS as a safe treatment. This now settled view is shared by
the National Institute of Health and Clinical Excellence
(NICE) (http://guidance.nice.org.uk/IPG314), the Na-
tional Health Service (NHS), and the major private insurance
companies. We understand that although UGFS is practiced
quite widely in the United States, the FDA has not yet
approved it. We have been performing UGFS in significant
numbers in theNHS since 2004.Thehypothesiswewished to
test is that UGFS is a safe and durable treatment for SVR
associated with CEAP clinical grade 2-6 disease.
METHODS
Patients
Local ethical committee approval and written informed
consent were obtained. Since March 23, 2004, consecutive
UK NHS patients referred by their general practitioners
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22 have been
enrolled in a dedicated follow-up program. Data have been
prospectively entered into a computerized database. Treat-
ment is not offered on the NHS for purely cosmetic indi-
cations or, usually, for non-truncal reflux. Thus, all study
patients had physical symptoms and signs secondary to
venous hypertension as a result of significant (0.5 sec-
onds) reflux on duplex ultrasonography (DUS) in one or
more of the following segments: great saphenous vein
(GSV); anterior accessory saphenous vein (AASV); small
saphenous vein (SSV); vein of the popliteal fossa (VOPF);
or Giacomini vein (GV). Patients with an ankle-brachial
pressure index 0.8 or significant postthrombotic deep
venous disease are not offered UGFS; such patients are
treated conservatively in the majority of cases.
UGFS technique
All the cases were undertaken by two vascular surgeons
(A.W.B. and D.J.A.) who used an identical technique that
has been described in detail elsewhere.10-14 However, to
summarize, following informed written consent, incompe-
tent truncal veins, their major tributaries, and superficial
varices are marked using DUS.12 With the patient supine,
18, 20, or 22G cannulae (Optiva 2; Smith’s Medical,
Watford, UK) are inserted into the marked veins under
DUS using local anesthetic. The cannulas are usually, but
not always, pointing cranially. Tumescent anesthesia is not
used. We elevate the leg as high as possible (usually 30-45
degrees) bearing inmind patient comfort and flexibility. Air
(2 mL) and 0.5 mL of sodium tetradecyl sulphate (STS)
(Fibrovein; STD Pharmaceuticals, Hereford, UK) is agi-
tated 10 times between two 2 mL syringes connected by a
three-way tap and a 5-micron filter (B Braun Medical,
Sheffield, UK) to produce foam (Tessari technique). Inter-
fascial trunks and major tributaries are usually treated with
3%, and extrafascial veins usually with 1%, STS foam. Foam
aliquots (2-2.5 mL) are injected slowly over 10 to 15
seconds though each cannula in turn usually working prox-
imal to distal on the leg. With the leg elevated, the foam
often spreads upward. Therefore, when one has injected,
for example, the proximal thigh GSV one often finds foam
in calf varices. However, other practitioners commence
injections distally, and we are not aware of any data that
indicate the superiority of one method over the other.
We aim to introduce “fresh” foam every 15 to 20 cm
down the trunk vein and major tributaries to be treated,
although there is no evidence to support that specific
distance. The progress of the foam is followed carefully
with DUS. By injecting slowly, waiting for spasm to occur
and applying pressure over junctional and nonjunctional
perforators, the volume of foam used and the deep passage
of foam can be minimized. If foam is observed in commu-
nicating or axial veins below the fascia, the injection is
stopped and the patient asked to dorsi- and plantar-flex his
or her ankle. Only when the foam has cleared are foam
injections recommenced. In addition, the patient dorsi-
and plantar-flexes his or her ankle 10 times between each
injection. We leave a minimum of 30 seconds between eachinjection. Although this is a non-evidenced-based time
period, the rationale is to minimize the amount of foam
being used. It takes about 15 to 20 seconds to make each
aliquot. Unpublished experimental studies suggest that it
takes about 20 to 30 seconds for STS to exert its full effects
(spasm and destruction of the endothelium) before being
deactivated through protein binding.
The total volume of foam used depends, of course,
upon the size of the veins and to what extent they collapse
when the leg is elevated and foam is injected (reduction in
dead space through reduced venous pressure and spasm).
However, typically 1 mL of foam (0.25 mL STS) is treating
about 7.5 to 10 cm of vein. However, rather than try to
achieve some arbitrary foam volume/vein length “dose”
we recommend introducing sufficient foam such that all
veins are in spasm and full of foam as observed by DUS.
Rolls of orthopedic wool are then applied over the
trunk and major tributaries and held in place with light-
weight non-stretch bandage (Peha-Haft; Paul Hartmann
Ltd, Heywood, UK). A full-length class II stocking (Cre-
delast; Credenhill, Ilkeston, UK) is fitted and held in place
with a waistband. This bandage-stocking combination pro-
duces a mixture of concentric and eccentric, elastic and
inelastic compression, and is applied while the leg is still
elevated. The patient then stands, gets dressed, and imme-
diately walks around the treatment center for 15 minutes
before reporting back; if all is well, he or she goes home.We
advise on the way home that he or she gets out of the car
every hour and walks around for 10 minutes; and then that
he or she walks a minimum of 5 minutes every hour he or
she is awake for the first week.
The bandage and stocking are left intact for 5 or 7 days,
depending on the size of the veins, after which they are
removed and a clean class II stocking is refitted and worn
for the remainder of the first month. For 1 week, it is worn
24 hours; for the last 2 weeks, the stocking can be removed
at night. Patients are provided with a 24/7 “help-line”
telephone number.
Although not evidenced-based, at the end of the pro-
cedure once compression has been applied, a single dose of
subcutaneous low-molecular weight heparin (LMWH) (20
mg-40 mg enoxaparin, Clexane; Sanofi Aventis, Guildford,
United Kingdom) is given selectively to older, immobile
patients; those with confirmed previous deep vein throm-
bosis (DVT); those with CEAP 5-6 disease; and in those
with known inherited or acquired thrombophilia. Antico-
agulants (warfarin) and antiplatelet agents (aspirin, clopi-
dogrel) are not discontinued. Antibiotics are not given
except in the rare case where an ulcer is infected with
-hemolytic streptococcus or Staphylococcus aureus. Only
one patient has required another form of treatment and
that was phlebectomy (please see below).
Most patients are offered a review appointment at 1
month. However, we often see older, frailer patients, espe-
cially those with CEAP C5/6 disease, back at 5 to 7 days to
remove the bandages, dress the ulcer as required, and refit
the stocking. Patients who telephone before 1 month are
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ally the situation can be dealt with by telephone.
Outcome measures and follow-up
Patients attend the clinic at 1 and 12 months and then
annually but are encouraged to contact us through the
“help-line” at any time should they have concerns; wish a
further assessment or treatment; or experience any side
effects or problems. Patients are specifically asked about
visual disturbance and any other neurologic symptoms.
Repeat DUS is performed at each follow-up visit. Patients
found to have residual, recurrent (recanalization), or new
truncal reflux are offered further UGFS.
RESULTS
Patients and first UGFS treatments
Patients, legs, and reflux. Between March 23, 2004
and December 31, 2009, 977 patients (1252 legs) under-
went a first UGFS for unilateral (702 legs) or bilateral (550
legs) SVR in association with CEAP clinical grade 2-3 (n
868), 4 (n  232), or 5/6 (n  152) disease. Seventeen
patients had suffered bleeding; two were treated as an
emergency for major hemorrhage that had led to hospital
admission. There were 638 left and 614 right legs. There
were 810 female legs of mean age (range) 53.2 (16-88)
years and 442 male legs of mean age (range) 55.2 (20-87)
years. Legs treated were 36 in 2004 (from March), 125 in
2005, 244 in 2006, 300 in 2007, 300 in 2008, and 247 to
end 2009. The following reflux was treated: primary GSV
(n  745), recurrent GSV (n  286), primary SSV (n 
189), recurrent SSV (n  50), primary AASV (n  93),
recurrent AASV (n 46), VOPF (n 5), and GV (n 3).
Overall, 348 (27.8%) legs had been previously operated at
least once for truncal VV in the same system. One leg had
previously undergone unsuccessful RFA elsewhere. Fifteen
legs had been previously affected by confirmed DVT.
Twelve patients were treated while on warfarin, (INR 2.5-
4.5) for previous DVT (10); atrial fibrillation (1), and a
mechanical aortic valve (1).
Numbers of cannulae. Prior to 2006, most proce-
dures were undertaken with one cannula at the mid-point
of the vein (usually GSV) to be treated. From 2006, the use
of multiple cannulas became increasingly common and
more patients were treated for SSV and AASV reflux. In
986 first UGFS treatments undertaken after January 1,
2006, the number of cannulae used were: one (n 108), 2
(n  289), 3 (n  245), 4 (n  159), 5 (n  87), 6 (n 
49), 7 (n 29), 8 (n 13), 9 (n 4), 10 (n 2), and 11
(n  1).
Volume and concentration of foam. In 1017 first
UGFS treatments undertaken after January 1, 2006, 3%
STS foam was used in 803; 3% and 1% STS foam was used
in 186; and 1% STS foam was used in 28 treatments. The
volumes of 3% and 1% STS foam used are shown in Fig 1.
Fifteen patients were also treated with 0.5% STS (volume
range 4-8 mL); this was always in combination with 3%
and/or 1% STS.One-month follow-up
At 1 month, 141 (11.3%) patients failed to attend and
1056 (84.4%) reported no complications or side effects.
Thirty (2.4%) legs underwent duplex-guided aspiration of
retained thrombus (2-5 mL) under local anesthesia. Three
patients complained of “lumpy” legs but declined aspira-
tion. Three reported they had suffered “phlebitis,” but this
had settled spontaneously. At the clinic, no specific treat-
ment other than topical nonsteroidal anti-inflammatory gel
was deemed necessary. One had been prescribed antibiotics
by his or her family doctor. One complained of headaches
and nosebleeds but this predated UGFS and settled spon-
taneously without specific treatment. One complained of
an “allergy” to the stocking that was probably an area of
pressure erythema and settled spontaneously. One devel-
oped a facial rash after 24 hours that disappeared sponta-
neously and no treatment was necessary. Three complained
of pain in the treated leg that was musculoskeletal and/or
stocking-related. One developed an in-grown toenail that
may have been related to compression; this was treated
conservatively and settled quickly. Five complained of tran-
sient visual disturbance at the time or shortly after treat-
ment; one patient had developed this twice (after each leg
was treated). These were all self-limiting and no other
neurology was reported or recorded. Three complained of
headache immediately following treatment. Two of these
were known to suffer frommigraine. All settled with simple
analgesia within 24 hours. At 1 month, six truncal veins
remained at least partially patent and were still refluxing;
one declined further treatment; one requested surgery (this
was multiple phlebectomies and the only “cross-over” to
another treatment modality); three underwent immediate
repeat (successful) UGFS; and one underwent immediate
repeat (unsuccessful) UGFS and then went on to have a
third session of UGFS which was successful. It is possible
that there was an issue with compliance with compression
Fig 1. Volume of 3% and 1% sodium tetradecyl sulphate (STS)
foam used in 1017 first ultrasound-guided foam sclerotherapy
(UGFS) treatments performed after January 1, 2006.in this last patient.
enous
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embolus
Three patients developed symptomatic DVT and one a
symptomatic pulmonary embolus (PE), all during the first
month following treatment (Table I). No asymptomatic
DVT were detected on DUS during follow-up. It is possi-
ble to speculate that the PE might have been avoided had
first follow-up been conducted prior to 4 weeks.
Deaths
Six patients have died since treatment: one following
revisional hip arthroplasty; one from colon cancer; one
from cardiac and renal failure 3 years post-foam; one from
rectal carcinoma 9 months post-foam; two patients treated
for C6 died ulcer free of old age at 90 and 91 years 2 and 4
years after UGFS, respectively.
Further UGFS treatments
During a mean (range) follow-up of 28 (1 to 68)
months, 161 (12.9%) legs underwent a further session of
UGFS for truncal VV at a mean (range) of 17 (1 to 63)
months. Of these, 122, 14, and 25 had initially undergone
UGFS for GSV, AASV, and SSV reflux, respectively. Sec-
ond UGFS treatments were performed for recurrent reflux
(recanalization) in 109 legs and for new reflux in a previ-
Table I. Deep vein thrombosis and pulmonary embolus a
Patient 1 A 58-year-old woman who underwent UGFS for p
STS foam delivered through a single cannula pla
significant past medical history, no known proth
UGFS. The patient had undergone uneventful U
treatment she returned with pain in the leg and
level of the sapheno-popliteal junction (SPJ). Th
and then warfarin for 6 months. The popliteal ve
asymptomatic. At 36 months following UGFS, t
required.
Patient 2 A 58-year-old woman who underwent UGFS for p
STS foam delivered through two cannulae place
undergone uneventful UGFS of right primary G
predisposition, and all deep veins were normal p
arthropathy. Three days after the second treatme
following the RTA, a DVT affecting the mid sup
with low molecular weight heparin (LMWH) an
At 24 months following UGFS, the SFV had par
occluded and there were no visible VV. There w
circumference.
Patient 3 A 65-year-old woman and heavy smoker (50 pack
She underwent UGFS for primary right GSV CE
through six cannulae. Three weeks following tre
physicians with left sided chest pain. She was dia
She was prescribed antibiotics and discharged th
problems. Chest X-ray at this time showed that t
angiogram that revealed a small left lower lobe P
anticoagulated and discharged home. Both her f
Patient 4 A 44-year-old obese woman who underwent UGF
mL of 3% and 8 mL of 1% STS foam delivered th
and extensive superficial varices. She attended A&
diagnosed with a calf vein DVT (posterior tibial
She is asymptomatic in the treated leg but has ye
DUS, Duplex ultrasonography; GSV, great saphenous vein; SSV, small saphously untreated vein in 52 legs (Table II).Freedom from reintervention for all 1417 treated trun-
cal segments is shown in Fig 2. There was no significant
difference in overall (recurrent and new reflux combined)
retreatment rates following first UGFS for GSV and SSV
reflux (Fig 3) or following first UGFS for primary or
recurrent disease (Fig 4). However, the recanalization rate
was significantly lower following first UGFS for AASV than
for GSV reflux (P  .044, Fisher exact test, two tailed).
There was no significant difference in recanalization rates
between GSV and LSV or between AASV and LSV reflux
(Table II).
A third UGFS treatment was undertaken in 14 legs
between 5 and 42 months after the second treatment. In
nine legs, this was for further recanalization (GSV eight
legs, SSV one leg) and in five legs, this was for a new disease.
There were no recorded significant side effects or compli-
cations following these second or third treatments.
DISCUSSION
Until some 5 years ago, most UK vascular surgeons had
dismissed sclerotherapy as an effective treatment for truncal
VV.23 Therefore, when approached to take part in the
Varisolve European Phase III trial, we were reasonably
confident of the likely outcome. However, it became rap-
idly apparent that UGFS could effectively eradicate SVR
ltrasound foam sclerotherapy
y left SSV CEAP C2 VV in November 2006 using 6 mL of 3%
the SSV at its midpoint in the posterior calf. There was no
otic predisposition, and all deep veins were normal prior to
of right primary SSV a month earlier. One week following
showed a 4 cm occlusive thrombus in the popliteal vein at the
ient was treated with low molecular weight heparin (LMWH)
canalized but does now exhibit reflux although the patient is
V remains occluded and no further treatment for VV has been
y left GSV CEAP C2 VV in October 2007 using 8 mL of 3%
he GSV at mid-thigh and just below the knee. The patient had
month earlier. There was no known prothrombotic
UGFS. The patient was on methotrexate for psoriatic
e patient was involved in a road traffic accident (RTA). Two days
al femoral vein (SFV) was diagnosed. The patient was treated
n warfarin for 12 months. Thrombophilia testing was negative.
recanalized and exhibited moderate reflux. The GSV remained
o skin changes or swelling, both calves being of equal
with a history of previous right leg superficial thrombophlebitis.
2 VV in June 2009 using 12 mL of 3% STS foam delivered
t, the patient was admitted under the care of the respiratory
d as having pneumonia, which was confirmed on chest X-ray.
e day. She attended A&E 2 weeks later with further breathing
ngs were clear. She was admitted and underwent CT pulmonary
e was also diagnosed with swine flu at this time. She was
and son have had confirmed PE in the past.
recurrent right GSV CEAP C4 VV in September 2009 using 8
h six cannulae, two placed in the GSV and four in the very large
weeks posttreatment complaining of pain in the leg and was
eroneal veins) and commenced LMWH and 3 months warfarin.
ttend 12-month DUS follow-up.
vein; UGFS, ultrasound-guided foam sclerotherapy.fter u
rimar
ced in
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GFS
DUS
e pat
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t to aand offered significant advantages over surgery.15 So, when
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made” foam. The number of patients referred for UGFS
increased rapidly, partly because we attracted work from
elsewhere but also because many people who would not
contemplate surgery wanted UGFS. Nevertheless, we were
still concerned about deep propagation of sclerothrombus
and a high recanalization rate. Therefore, fearing venous
thromboembolic (VTE) complications and the need to
Numbers at risk 1417 1079 680 360 125 25 
% free of re-treatment 100 96 92 88 85 81 
Fig 2. Kaplan-Meier plot showing freedom for any reintervention
of all 1417 treated venous segments.
Table II. Second UGFS treatments for recurrent
(recanalization) and new reflux
First treatment
GSV reflux
N  1031
AASV reflux
N  139
SSV reflux
N  239
Legs (%) requiring
second UGFS 122 (11.8) 14 (10.1) 25 (10.5)
Mean (range)
follow-up
(months)
41 (6-
68) 35 (8-64) 32 (9-66)
Recurrent reflux
(n  109)
GSVa 87 — —
AASV — 5 —
SSV — — 17
Recanalization
rate 8.4% 3.6% 7.1%%
New reflux
(n  52)
GSVb 13 9 6
AASV 14
SSV 8
VOPF — — 2
GV
New reflux rate 3.4% 6.5% 3.4%
AASV, Anterior accessory saphenous vein; GSV, great saphenous vein; GV,
Giacomini vein; SSV, small saphenous vein;VOPF, vein of the popliteal fossa.
aIn previously treated above knee and/or below knee segment of GSV.
bIn previously untreated below knee segment of GSV.“redo” surgery, we built the UGFS practice slowly andestablished a research-funded review program. Our fears
were unfounded and soon we were treating some 300 legs
per annum.More recently, the numbers have fallen because
of NHS rationing.9,24
Undertaking outcomes research in patients being
treated for VV is difficult as they are often young, mobile,
and employed and so reluctant or unable to attend follow-
up. That said, we believe that our follow-up compares
GSV Numbers at risk 1031 791 516 274 96 19 
 % free of re-treatment 100 96 92 88 84 82 
SSV Numbers at risk 239 180 116 60 20 5 
 % free of re-treatment 100 95 92 88 84 74 
Fig 3. Kaplan-Meier plot comparing freedom from any re-
intervention in patients undergoing ultrasound-guided foam scle-
rotherapy (UGFS) for great saphenous vein (GSV) (n 1031) and
SSV (n 239) reflux (P .701 log-rank test, 95% CI 4.94-5.20).
Primary Numbers at risk 1035 782 488 273 92 22 
 % free of re-treatment 100 96 93 88 82 81 
Recurrent Numbers at risk 382 295 192 87 27 11 
 % free of re-treatment 100 95 91 88 86 82 
Fig 4. Kaplan-Meier plot comparing freedom from any re-
intervention in patients undergoing ultrasound-guided foam scle-
rotherapy (UGFS) for primary (n  1035) and recurrent disease
(n  382) (P  .884 log-rank test; 95% CI 4.97- 5.27).favorably with the rest of the literature.10-14 Patients who
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time should they have any concerns or want further assess-
ment or treatment. Had we not worked so hard to maintain
contact with the patients we may have reported lower
retreatment rates. Standard NHS practice is not to follow
patients after VV surgery.
The VTE complication rate compares well with that
reported after surgery, RFA, and EVLT; especially bearing
in mind of the numbers of older C5/C6 patients.25-28 All
symptomatic DVT/PE occurred within 1 month. No
asymptomatic DVTs were observed. It is possible that some
DVTs were missed, either because they had resolved before
the 1-month follow-up, or occurred between follow-up
visits; or because they occurred in patients who defaulted
from the clinic. However, it seems unlikely that we are
missing significant post-UGFS VTE complications.
Five patients had transient visual disturbances, all self-
limiting. We observed no other neurologic or other signif-
icant adverse events. This supports the view that the risks of
micro-embolism leading to clinically significant adverse
outcomes are negligible.29,30 We have not, therefore,
changed from air to carbon dioxide.31 We undertake no
cardiac assessment prior to UGFS and believe that none is
necessary.
UGFS creates a controlled thrombophlebitis and every
attempt should be made to retain foam within the superfi-
cial venous system; any foam observed deep to the fascia
should be cleared as quickly as possible.32 Despite good
compression, some patients develop redness and pain over
the treated veins, especially in large extrafascial varices close
to the skin. In these, 0.5% or 1% STS foam usually achieves
occlusion without undue perivenous inflammation. We
have adopted an ever lower threshold for DUS-guided
aspiration of semi-liquid, sclerothrombus during the first
weeks after treatment. It provides instant symptom relief
and reduces skin pigmentation, which can develop in up to
a third of patients. We inform patients that this may occur
and that it will fade over a few weeks or months; only rarely
is it permanent.11,13
One of the difficulties with interpreting the UGFS
literature is that techniques vary considerably.33 When
teaching UGFS, we stress the importance of minimizing
foam volumes34 and concentrations35 of sclerosant; multi-
ple cannulae to deliver “fresh” foam to each segment of
vein (we know foam is quickly de-activated upon contact
with blood and endothelial protein); DUS to ensure veins
are in spasm and full of foam; the techniques to minimize
the spread of foam to the deep venous system; and good
compression.
Retreatment rates after UGFS are low and compare
favorably with those reported after surgery, RFA, and
EVLT.36-39 Redo UGFS is much simpler and easier than
redo surgery, RFA, or EVLT.
About a third of secondary treatments were for the
development of new disease. Reflux in the below knee (BK)
GSV is one such cause of “recurrence”40 and we now often
treat the whole GSV, even if there is no reflux below knee.
Similarly, when treating AASV we will often treat the AKGSV as well, even if it is competent; and when treating AK
GSV reflux we make a point of occluding the AASV, too, if
present.
We do not, of course, claim that ourUGFS technique is
the only effective one or, indeed, necessarily the best.
However, through good patient communication, proce-
dural attention to detail, a low threshold for early aspiration
and repeat treatment, careful follow-up to detect new and
recurrent SVR and open telephone access to patients,
UGFS has now virtually replaced all other forms of treat-
ment for SVR in our practice. UGFS has the advantage of
being extremely versatile, a “complete” treatment usually
achieved in one session, and extremely cost-effective. By
contrast, we find many patients are unsuitable for catheter-
based techniques and many patients undergoing RFA or
EVLA require supplementary procedures; they are also
much more expensive.
In conclusion, present outcome data on 1252 consec-
utive legs in 977 patients treated with UGFS over a 5- to
6-year period contribute to the growing worldwide body of
evidence that UGFS is a safe, durable, and highly cost-
effective treatment for SVR. As with all treatments for SVR,
patients are at some, albeit low, risk of developing recurrent
and new reflux after UGFS and should be kept under
regular review. Further UGFS for new or recurrent disease
is simple, safe, inexpensive, and highly effective.
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